Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Clinical targeting of the altered metabolism of tumor cells has long been considered an attractive hypothetical approach. However, this strategy has yet to perform well clinically. Metabolic redundancy is among the limitations on effectiveness of many approaches, engendering intrinsic single-agent r...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Acceso en liña: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0269620&type=printable |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|